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Transplantation Recipients
Drew J. Winston, Kathy Bartoni, Mary C. Territo, Gary J. SchillerBased on favorable results from randomized clinical trials, oral posaconazole has been approved for prophy-
laxis in neutropenic patients and stem cell transplantation (SCT) recipients. However, routine use of a pro-
phylactic drug may yield different results than those from clinical trials. We collected data on the efficacy,
safety, breakthrough infections, and antimicrobial resistance associated with standard long-term posacona-
zole prophylaxis in adult allogeneic SCTrecipients at the UCLA Medical Center. Oral posaconazole (200 mg
3 times daily) was started on day 1 after SCTand continued until day 100. After day 100, posaconazole was
continued in patients who still required corticosteroids for prevention or treatment of graft-versus-host dis-
ease. From January 2007 through December 2008, 106 consecutive patients received prophylactic posaco-
nazole. Breakthrough invasive fungal infections on posaconazole occurred in 8 patients (7.5%) within 6
months after SCT; 3 additional patients developed invasive fungal infection after discontinuation of prophy-
lactic posaconazole. The infective organisms were Candida (8 cases), Aspergillus (2 cases), and Aspergillus plus
Coccidioides immitis (1 case). There were no Zygomycetes infections. Only 2 (both Candida glabrata) of 9 infect-
ing isolates tested were resistant to posaconazole (minimal inhibitory concentration .1 mg/mL). Mortality
from invasive fungal infection occurred in 4 patients (3.7%). Except for nausea in 9 patients, no clinical adverse
event or laboratory abnormality could be attributed to posaconazole. Mean peak and trough plasma posa-
conazole concentrations were relatively low (\400 ng/mL) in neutropenic patients with oral mucositis and
other factors possibly affecting optimal absorption of posaconazole. These results demonstrate that standard
long-term oral posaconazole prophylaxis after allogeneic SCT is safe and associated with few invasive mold
infections. However, breakthrough infections caused by posaconazole-susceptible organisms (frequently
Candida) may occur at currently recommended prophylactic doses. Thus, strategies to improve posacona-
zole exposure, including the use of higher doses, administration with an acidic beverage, and restriction
of proton pump inhibitors, need to be considered when using prophylactic posaconazole.
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Invasive fungal infections can be a common cause
of morbidity andmortality after allogeneic hematopoi-
etic stem cell transplantation (SCT). During the past
decade, significant changes in both the epidemiology
and risk factors for these infections have occurred.Division of Hematology-Oncology, Department of Med-
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6/j.bbmt.2010.04.017Aspergillus, Zygomycetes, and other molds have now sur-
passed Candida organisms as the predominant cause of
invasive fungal infections in allogeneic SCT recipients
[1-3]. The majority of cases of invasive candidiasis are
now caused by non-albicans species of Candida. Recent
changes in transplantation practices also have greatly
increased the number of transplant recipients at high
risk for invasive fungal infections. The older age
of many current transplant recipients, increased use
of unrelated donors and cord blood (CB) as a source of
stem cells, and more intense immunosuppression with
high-dose corticosteroids and antithymocyte globulin
to prevent or treat severe graft-versus-host disease
(GVHD) have all contributed to an increased risk for
invasive fungal infections [4]. At many transplant
centers, invasive fungal infection is the leading cause
of death from infection [5].507
508 Biol Blood Marrow Transplant 17:507-515, 2011D. J. Winston et al.Based on the results of randomized studies per-
formed in the 1990s and several published guidelines,
fluconazole is commonly used for antifungal prophy-
laxis in allogeneic SCT recipients [6-8]. However,
a major limitation of fluconazole prophylaxis is the
lack of activity against Aspergillus and other molds.
Indeed, in several recent randomized clinical trials,
azole agents active against molds (eg, itraconazole,
voriconazole) were shown to be more effective than
fluconazole for preventing aspergillosis in allogeneic
SCT recipients [9-11]. Consequently, at the UCLA
Medical Center, we have routinely used a mold-active
azole for antifungal prophylaxis in all adult allogeneic
SCT recipients since 2002 [12,13]. Both itraconazole
and voriconazole have been effective in preventing
Aspergillus infections as well as Candida infections.
However, the effectiveness of oral itraconazole solution
has been limited by gastrointestinal intolerance [9,10],
whereas breakthrough Zygomycetes infections have been
problematic in patients on long-term voriconazole pro-
phylaxis at both the UCLA Medical Center and other
transplant centers [14-16].
Posaconazole is a relatively new oral triazole agent
with an enhanced spectrum of in vitro activity against
a wide range of medically important fungi, including
Candida, Aspergillus, the emerging Zygomycetes, and
other filamentous fungi [17]. In 2 multicenter,
double-blinded trials involving either allogeneic SCT
patients with GVHD or nontransplantation patients
with a hematologic malignancy and prolonged neutro-
penia, posaconazole was superior to fluconazole in
preventing invasive aspergillosis and death from inva-
sive fungal infection [18,19]. In addition, a study of the
pharmacokinetics and safety of oral posaconazole in
neutropenic SCT recipients showed that posaconazole
is systemically available, safe, and well tolerated
immediately after transplantation [20]. In view of these
results and our experience with the limitations of oral
itraconazole solution and voriconazole for prophy-
laxis, we introduced in 2007 long-term oral posacona-
zole as standard antifungal prophylaxis in all adult
allogeneic SCT recipients at UCLA Medical Center.
Prophylactic posaconazole is used both during the
neutropenic period immediately after transplantation
and for several months after engraftment. We report
the efficacy, safety, breakthrough infections, and anti-
microbial resistance associated with this routine pro-
phylaxis with posaconazole.METHODS
We collected data from 106 consecutive adult pa-
tients who received prophylactic oral posaconazole af-
ter undergoing allogeneic SCT at the UCLA Medical
Center between January 1, 2007, and December 31,
2008. Data were collected for up to 6 months aftertransplantation. The data collection was approved by
UCLA’s Human Subject Protection Committee.
All patients were given high-dose chemotherapy
alone or with radiation therapy, followed by i.v. infu-
sion of stem cells from a related donor or an unrelated
donor. Cyclosporine alone or in combination with cor-
ticosteroids, methotrexate, ormycophenolate was used
to prevent GVHD. Patients who developed GVHD
were evaluated using standard criteria and treated
with either corticosteroids or increased doses of
their maintenance immunosuppressive drugs. After
engraftment, trimethoprim-sulfamethoxazole, or ato-
vaquone in patients intolerant of trimethoprim-
sulfamethoxazole, was given to prevent Pneumocystis
pneumonia. Similarly, except for 34 patients participat-
ing in a study of prophylactic maribavir [21], i.v. ganci-
clovir (cytomegalovirus [CMV]-seropositive patient or
donor) or CMV-seronegative blood products (CMV-
seronegative patient with a CMV-seronegative donor)
was used to prevent CMV disease. Intravenous immu-
noglobulin was administered to patients with an unre-
lated ormismatched donor and to any patient aged.40
years for modification of GVHD. Patients receiving
corticosteroid therapy for the prevention or treatment
of GVHD and patients with severe epigastric symp-
toms received the proton pump inhibitor pantoprazole.
Oral posaconazole suspension (200 mg 3 times
daily) was administered with meals whenever possible,
beginning on day 1 after SCT and continuing until day
100. After day 100, posaconazole was continued in
those patients who still required corticosteroids for
prevention or treatment of GVHD. If a patient could
not take the oral drug, i.v. itraconazole (200 mg i.v.
every 12 hours for 2 days, followed by 200mg i.v. every
24 hours) was temporarily substituted for oral posaco-
nazole. When i.v. itraconazole became unavailable in
the United States, i.v. voriconazole (6 mg/kg i.v. every
12 hours for 1 day, followed by 4 mg/kg i.v. every
12 hours) was used as a temporary replacement for
posaconazole.
All patients were followed closely for the develop-
ment of fungal infections. Cultures of blood and other
suspected sites of fungal infection, computed tomogra-
phy scans of the chest and abdomen, and blood
specimens for the Aspergillus galactomannan assay
(Platelia; Bio-Rad Laboratories, Redmond, WA) were
obtained to evaluate patients whose clinical condition
suggested the possibility of fungal infection. Based
on the results of these diagnostic studies, other sys-
temic antifungal agents were started for treatment of
invasive fungal infection. Invasive fungal infections
were diagnosed using the consensus criteria estab-
lished by the European Organization for Research
and Treatment of Cancer and the Mycoses Study
Group [22].
Fungal isolates causing invasive fungal infection
were tested for susceptibility to posaconazole and other
Table 1. Patient Characteristics
Number of patients 106
Median age, years (range) 46 (18-64)
Sex, male/female, n 56/50
Underlying disease
Acute leukemia 60 (57)
Biol Blood Marrow Transplant 17:507-515, 2011 509Standard Posaconazole Prophylaxis in Stem Cell Transplantationantifungal agents by a microbroth dilution assay, in
accordance with Clinical Laboratory Standards
Institute standards [23,24]. Plasma concentrations of
posaconazole were determined using a validated high-
performance liquid chromatography method [25].Lymphoma 16 (15)
Myelodysplastic syndrome 13 (12)
Chronic myelogenous leukemia 8 (7)
Aplastic anemia 6 (6)
Other* 3 (3)
Advanced hematologic disease 59 (56)
Donor type
Related 61 (58)
Unrelated 45 (42)
HLA matching
Matched 78 (74)
Mismatched 28 (26)
Stem cell source
Peripheral blood 60 (57)
Cord blood 28 (26)
Bone marrow 18 (17)
Transplant type
Myeloablative 93 (89)
Nonmyeloablative 13 (11)
Conditioning regimen
Chemotherapy alone 57 (54)
Radiation and chemotherapy 49 (46)
GVHD prophylaxis
Cyclosporine, corticosteroids, methotrexate 51 (48)
Cyclosporine, mycophenolate 27 (25)
Cyclosporine, methotrexate 11 (10)
Cyclosporine alone 13 (12)
Cyclosporine, corticosteroids, mycophenolate 2 (2)
Tacrolimus, methotrexate, or mycophenolate 2 (2)
Mean duration of neutropenia (neutrophil count
<500 cells/mm3), days (range)
19.6 (2-117)
Oral mucositis during neutropenia 90 (85)
Acute GVHD
None (grade 0-I) 42 (40)
Yes (grade II-IV) 64 (60)
Chronic GVHD
None 82 (77)
Yes 24 (23)
Corticosteroids for prevention or treatment of GVHD 81 (76)
CMV disease 1 (0.9)
GVHD indicates graft-versus-host disease.
Data are n (%) of patients unless specified otherwise.
*Plasma cell leukemia, chronic lymphocytic leukemia, and histiocytic
sarcoma.RESULTS
Table 1 summarizes the characteristics of the 106
patients who received standard antifungal prophylaxis
with posaconazole. These patients had many of the
characteristics associated with high risk for invasive
fugal infection after allogeneic SCT, including older
age (median age, 46 years), advanced hematologic
disease (56%), unrelated donor (42%), mismatched
donor (20%), use of CB as the stem cell source
(26%), myeloablative conditioning regimen (89%),
treatment with high-dose corticosteroids (76%), and
acute GVHD (aGVHD; 60%). The mean duration
of neutropenia was 19.6 days. 85% of the patients
had oral mucositis during the period of neutropenia
immediately after transplantation and before engraft-
ment. The proton pump inhibitor pantoprazole was
used in .90% of the patients.
The mean duration of prophylaxis with posacona-
zole was 113 days (range, 1-180 days). Because of
severe oral mucositis or inability to take oral medica-
tion, 34 patients (32%) were temporarily changed to
either i.v. itraconazole or i.v. voriconazole (mean dura-
tion, 9.6 days; range, 3-24 days).
Within 6months after transplantation, 8 of the 106
patients (7.5%) developed a breakthrough invasive
fungal infection while on prophylactic posaconazole
(Table 2). Three other patients had an invasive fungal
infection between 53 and 66 days after completion of
posaconazole prophylaxis (Table 3). These 3 patients
developed infections while receiving another systemic
antifungal agent. Two of these patients were restarted
on antifungal prophylaxis with oral voriconazole or
fluconazole by their primary physician at 2 months
after discontinuation of posaconazole. Another patient
with aGVHD and severe renal failure was changed to
prophylaxis with i.v. caspofungin when he could no
longer take oral posaconazole or an i.v. azole drug.
The median time of onset of the 11 invasive fungal in-
fections was day 65 after transplantation (range, 2-162
days after transplantation). Three infections occurred
within 2 weeks after transplantation, before engraft-
ment. Factors associated with breakthrough infections
included neutropenia (4 cases), infected central i.v. line
(3 cases), poor compliance with oral medications (2
cases), administration of posaconazole through a gas-
tric tube (1 case), and engraftment failure (1 case).
GVHD was associated with 2 of the 3 infections that
occurred after discontinuation of posaconazole pro-
phylaxis. All 11 patients with an invasive fungalinfection were receiving the proton pump inhibitor
pantoprazole at the time of the infection, and 8 of these
11 patients had concurrent oral mucositis or diarrhea.
Candida species were the most common organisms
causing invasive fungal infection (8 cases), followed by
Aspergillus species alone (2 cases) and Aspergillus spe-
cies plus Coccidioides immitis (1 case) (Table 3). There
were no cases of zygomycosis. Of note, only 2 of the
9 infecting isolates tested for susceptibility were resis-
tant to posaconazole (minimum inhibitory concentra-
tion [MIC] .1.0 mg/mL). Both of these resistant
isolates were Candida glabrata. Caspofungin alone
was used to treat the Candida infections, whereas either
caspofungin plus voriconazole or amphotericin B lipid
complex alone was used to treat the Aspergillus infec-
tions. Four of the 11 infections were classified as fatal.
Two patients with candidemia complicating severe
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510 Biol Blood Marrow Transplant 17:507-515, 2011D. J. Winston et al.GVHD were not treated for their fungal infection, as
medical care was withdrawn because of the poor prog-
nosis of their GVHD.
Because previous studies of prophylactic oral
posaconazole in patients with neutropenia and patients
withGVHD demonstrated efficacy at a dose of 200mg
3 times daily, and a plasma concentration target
for prophylactic efficacy had not yet been estab-
lished [18,19], we initially did not monitor plasma
posaconazole levels in our patients. However, after
several patients developed breakthrough infections
caused by posaconazole-susceptible organisms, we
measured both peak and trough plasma posaconazole
concentrations on days 2, 8, and 15 after transplanta-
tion in 15, 14, and 10 neutropenic patients, respec-
tively. The clinical characteristics of the 19 patients
with plasma posaconazole levels included underlying
diseases of acute leukemia (9 patients), myelodysplastic
syndrome (5 patients), chronic myelogenous leukemia
(3 patients), and lymphoma (2 patients); advanced he-
matologic disease (10 patients); a conditioning regi-
men of chemotherapy alone (14 patients) or radiation
plus chemotherapy (5 patients); oral mucositis (15 pa-
tients); diarrhea (9 patients); and use of pantoprazole
(16 patients). The respective mean peak and trough
plasma posaconazole levels were 168 ng/mL and 121
ng/mL on day 2 posttransplantation, 306 ng/mL and
276 ng/mL on day 8, and 257 ng/mL and 211 ng/
mL on day 15. Three of the 19 patients in whom
plasma posaconazole levels were measured developed
an invasive fungal infection. One of these fungal
infections (Aspergillus pneumonia) occurred during
posaconazole therapy, whereas the other 2 infections
(candidemia) occurred after discontinuation of posa-
conazole. Plasma posaconazole levels in the patients
who subsequently developed invasive fungal infections
were similar to those levels in patients who did not
develop an invasive fungal infection.
Generally, oral posaconazole was well tolerated.
Except for nausea in 9 patients, we were unable to
attribute any adverse clinical event or laboratory
abnormality to posaconazole. Two of the 9 patients
with nausea temporarily stopped taking posaconazole,
but later resumed their antifungal prophylaxis with no
further drug-related adverse events. Similarly, posaco-
nazole was temporarily discontinued in 4 patients who
developed abnormally elevated serum bilirubin or
hepatic enzyme levels. However, in each of these cases,
the elevated level could be attributed to other causes
(ie, veno-occlusive disease or GVHD), and prophylac-
tic posaconazole was resumed with no further deterio-
ration of hepatic function.
At 6 months posttransplantation, overall patient
survival was 65%, and fungal-free survival (ie, freedom
from invasive fungal infection or death) was 62%.
Causes of death are summarized in Table 4. Relapse
of malignancy, GVHD, and infection were the most
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Table 4. Causes of Death
Number of patients 106
Number of deaths, n (%) 37 (35)
Relapse of malignancy, n 12
Toxicity of chemotherapy, n 5
GVHD, n 4
Infection, n 8
Bacterial sepsis 4
Invasive fungal infection 2
Invasive fungal infection, bacterial sepsis, GVHD 1
Invasive fungal infection, viral pneumonia, GVHD 1
Idiopathic interstitial pneumonia 3
Other* 5
*Thrombotic thrombocytopenia purpura, n 5 2; hemorrhage, n 5 1;
transfusion reaction, n 5 1; myocardial infarction, n 5 1.
Biol Blood Marrow Transplant 17:507-515, 2011 511Standard Posaconazole Prophylaxis in Stem Cell Transplantationcommon causes of death. Four deaths were associated
with invasive fungal infection (Aspergillus pneumonia,
Aspergillus plus Coccidioides pneumonia, and 2 cases of
candidemia) among the 106 patients (3.7%). However,
the 2 patients with candidemia were not treated for
their infection, as medical care was withdrawn because
of the poor prognosis of their GVHD plus other
infectious complications.DISCUSSION
Although debate is ongoing regarding the optimal
approach to the prevention of invasive fungal infec-
tions in allogeneic SCT recipients [26,27], recent
guidelines and consensus statements support the use
of prophylactic antifungal agents in these patients
[4,28,29]. In addition, the unique experiences of each
local transplant center must be considered when
designing effective strategies for reducing morbidity
and mortality from invasive fungal infections. For
many years, antifungal prophylaxis with fluconazole
was the standard at most transplant centers [6-8].
However, with the emergence of Aspergillus and
other molds as the most common causes of invasive
fungal infections after allogeneic SCT, and with
increasing number of high-risk patients undergoing
transplantation, fluconazole is now being replaced
with a mold-active agent for prophylaxis at many
transplant centers [4,26,28].
At the UCLAMedical Center, in both randomized
controlled trials and in routine clinical practice, we
have found that prophylaxis with a mold-active azole
is more effective than fluconazole for preventing inva-
sive fungal infections after allogeneic SCT [9,12,13].
Before the use of a mold-active azole became routine
practice, the incidence of invasive aspergillosis in allo-
geneic SCT patients at UCLA was approximately
15%; this dropped to\5% after the introduction of
mold-active prophylactic agents [12,13]. Because so
many of the allogeneic SCT recipients at UCLA
either receive high doses of corticosteroids early after
transplantation for prevention of GVHD or receive
an unrelated umbilical CB transplant with delayed
512 Biol Blood Marrow Transplant 17:507-515, 2011D. J. Winston et al.engraftment, we start mold-active azole prophylaxis on
day 1 after transplantation and continue prophylaxis
until day 100. After day 100, patients are maintained
on a mold-active azole if they are still receiving corti-
costeroids for prevention or treatment of GVHD.
A similar strategy is followed by other transplant
centers [4,10,30].
Itraconazole, administered either i.v. or as an oral
solution, was initially used successfully at UCLA to
prevent aspergillosis and other invasive fungal infec-
tions [12,13]. However, because of gastrointestinal
intolerance of the oral itraconazole solution and the
subsequent nonavailability of i.v. itraconazole in the
United States, oral and i.v. voriconazole briefly
replaced itraconazole for prophylaxis in many of our
allogeneic SCT patients. Unfortunately, similar to
the experience at other oncology centers [14-16], we
observed for the first time at UCLA the emergence
of Zygomycetes infections in patients who had been on
long-term voriconazole. For reasons of cost and lack
of an oral formulation, we have not used an echinocan-
din for antifungal prophylaxis [31].
We began using prophylactic posaconazole in all of
our allogeneic SCT patients in 2007, after posacona-
zole had been shown to bemore effective than flucona-
zole in preventing invasive fungal infections in
randomized controlled trials and had been approved
for antifungal prophylaxis in both neutropenic patients
and SCT patients [18,19]. As we report here, the
incidence of breakthrough invasive fungal infections
within the first 6 months after transplantation in
allogeneic SCT patients on standard prophylactic
posaconazole at UCLA was 7.5%. This incidence is
somewhat higher than the 2%-5.3% incidences
of invasive fungal infections reported in previous
randomized clinical trials of prophylactic posaconazole
[18,19], but is comparable to those reported in trials of
prophylactic itraconazole (7%-9%) and prophylactic
voriconazole (6.6%) after allogeneic SCT [9-11]. The
higher incidence of invasive fungal infections in our
UCLA patients on standard long-term prophylactic
posaconazole might be explained by the longer
follow-up of our patients, as well as by patient selection
factors in the clinical trials that were not applicable to
our routine use of posaconazole in all patients. Similar
patient selection factors, as well as differences in the
types of patients undergoing transplantation, also
might explain the higher 6-month mortality rate in
our patients (35%) compared with the rates reported
in clinical trials of prophylactic posaconazole (25%)
and prophylactic voriconizole (20%) after allogeneic
SCT [11,18]. A well-controlled randomized trial com-
paring posaconazole with voriconazole for antifungal
prophylaxis might be useful to address the relative
efficacy of these two agents, especially in preventing
breakthrough infections by Zygomycetes. We did not
find any cases of zygomycosis in this retrospective studyof UCLA patients on prophylactic posaconazole, but
the incidence of zygomycosis may vary among trans-
plant centers. Furthermore, despite posaconazole’s
superior in vitro activity for Zygomycetes species com-
pared with other azole antifungal agents, 2 cases of
beakthrough zygomycosis have been reported recently
in allogeneic SCT recipients receiving prophylactic
posaconazole [32,33].
Candida species were the most common organ-
isms causing breakthrough infections in our patients
both during and after discontinuation of posaconazole
prophylaxis (Tables 2 and 3). In contrast, only 3 of our
106 patients (2.8%) developed invasive aspergillosis, and
nonehadZygomycetes infection.Only2of the9organisms
causing infection and tested for susceptibility were
found to be resistant to posaconazole (MIC .1.0 mg/
mL). Both resistant isolates were Candida glabrata
organisms. In the 2 previous clinical trials of
prophylactic posaconazole, Candida glabrata was also
the colonizing species that most frequently exhibited
decreased susceptibility to posaconazole and caused
breakthrough infection [34]. Generally, there was
concordance in these 2 trials between the colonizing
Candida species in the gastrointestinal tract and the
species causing invasive infection, suggesting that the
route of infection was translocation of Candida species
across gastrointestinal mucosal surfaces damaged by
cytotoxic chemotherapy or GVHD. Similarly, al-
though 4 of the 8 cases of candidemia in our study
were clearly related to a central i.v. catheter infected
with the same Candida species as the blood isolate
(Tables 2 and 3), the other 4 cases of candidemia
were associated with oral mucositis, diarrhea, and/or
GVHD and thus were likely related to the transit of
colonizing organisms across damaged mucosal
surfaces.
The occurrence of breakthrough invasive fungal in-
fections caused by organisms still susceptible to posaco-
nazole in several of our patients suggests that these
patients may have had an inadequate plasma posacona-
zole concentration for effective prophylaxis. When we
started using standard prophylactic posaconazole in
2007, pharmacokinetic analyses in the patients partici-
pating in the trials of prophylactic posaconazole during
neutropenia and after SCTsuggested noneed for adjust-
ment of posaconazole dosage based on variables that
could affect absorption [35,36]. Furthermore, a plasma
posaconazole concentration for prophylactic efficacy
had not yet been established, although a study of
posaconazole salvage therapy for invasive aspergillosis
had suggested a relationship between posaconazole
concentration and response rate [37]. Consequently,
we initially did not perform therapeutic drug monitor-
ing. More recent pharmacokinetic studies in both
healthy volunteers and patients have suggested that
poor nutritional status, higher gastric pH, increased gas-
trointestinal motility, oral mucositis, and the use of
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tion of posaconazole [30,38,39]. Many of these factors
were operative in our UCLA patients receiving
standard long-term prophylactic posaconazole (Tables
2 and 3) and could have contributed to relatively lower
plasma levels of posaconazole and subsequent
breakthrough infections. Of note, one of our patients
(patient 1;Table 2) developed breakthrough candidemia
while receiving posaconazole administered through
a gastric tube. Lower plasma posaconazole concentra-
tions have been reported in healthy volunteers receiving
posaconazole via a nasogastric tube [40].
The development of several breakthrough invasive
fungal infections by posaconazole-susceptible organ-
isms eventually promptedus tomeasureplasmaposaco-
nazole concentrations. Because of financial issues
related to the cost of frequent plasma posaconazole
measurements, we confined our therapeutic drug mon-
itoring to the neutropenic period immediately after
transplantation. Neutropenic allogeneic SCT recipi-
ents experience many adverse events that could poten-
tially affect the absorption of posaconazole, yet there
are limited data on plasmaposaconazole concentrations
in these patients. Indeed, we found mean peak and
trough plasma posaconazole levels of\400 ng/mL in
our patients, lower than the levels reported in the 2 pre-
vious clinical trials of prophylactic posaconazole
[18,19,35,36]. Similar low plasma posaconazole levels
during routine use of posaconazole at recommended
doses have been noted by other investigators [41]. Con-
sequently, in an effort to improve the prophylactic effi-
cacy of posaconazole in our patients, we nowadminister
prophylactic posaconazole at a higher dose (400 mg
orally twice daily) in combination with an acidic bever-
age as well as meals [39]. Mean steady-state peak and
trough plasma posaconazole concentrations at day 15
after transplantation have been higher (543 ng/mL
and 410 ng/nL, respectively) in our patients receiving
posaconazole according to this amended protocol.
Although a higher mean plasma posaconazole level
(958 ng/mL) has been reported in SCT recipients
with aGVHD receiving posaconazole at a dose of 200
mg 3 times a day [18,36], we continue to administer
the higher dose of prophylactic posaconazole (400 mg
twice daily) with an acidic beverage and meals to our
patients after engraftment, to maximize posaconazole
exposure. This higher dose of posaconazole has been
well tolerated, but requires further evaluation in
additional pharmacokinetic studies. The development
of an i.v. posaconazole formulation also would likely
facilitate the achievement of effective posaconazole
concentrations for prophylaxis.
Except for nausea in a few patients, posaconazole
was well tolerated. There were no hepatotoxicity
or other laboratory abnormalities that we could attri-
bute to posaconazole. Because of a previous report
describing increased toxicities associated with theadministration of azole antifungal agents and certain
cytotoxic chemotherapeutic agents [42], we do not
administer prophylactic posaconazole during pre-
transplantation conditioning therapy.
In summary, our experience using posaconazole
for standard antifungal prophylaxis in allogeneic
SCT recipients demonstrates that the drug is safe
and generally well tolerated. Standard posaconazole
prophylaxis at UCLA is associated with very few inva-
sive Aspergillus infections and no apparent Zygomycetes
infections. However, breakthrough fungal infections
caused by posaconazole-susceptible organisms may
occur when posaconazole is used at currently recom-
mended prophylactic doses (200 mg orally 3 times
daily) in patients with factors that may adversely affect
absorption of the drug. Thus, strategies to improve
posaconazole exposure, including the use of higher
doses, administration with an acid beverage as well as
a meal or nutritional supplement, and restricting the
use of proton pump inhibitors, should be strongly
considered. Although the relationship between thera-
peutic drug monitoring with prophylactic posacona-
zole and improved clinical outcomes requires further
study, measurement of plasma posaconazole concen-
trations also should be considered in patients with
conditions that could seriously impair effective ab-
sorption of the drug. An i.v. formulation of posacona-
zole is needed to overcome some of the limitations of
prophylaxis with oral posaconazole. Finally, antifungal
strategies using other mold-active agents as either
prophylaxis or preemptive therapy based on results
of serum galactomannan assays and chest computed
tomography scan in high-risk patients have been
used successfully in SCT patients at other institutions
[11,27,31,43], and these options should be considered
if the use of prophylactic posaconazole is not suitable.ACKNOWLEDGMENTS
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